Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

1044800

USP

Atracurium besylate

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

2,2′-[1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinium]dibenzenesulfonate, BW-33A, Tracrium

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C65H82N2O18S2
Numéro CAS:
64228-81-5
Poids moléculaire :
1243.48
Numéro MDL:
MFCD00797403
Code UNSPSC :
41116107
ID de substance PubChem :
329749081
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

atracurium

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

[O-]S(=O)(=O)c1ccccc1.[O-]S(=O)(=O)c2ccccc2.COc3ccc(CC4c5cc(OC)c(OC)cc5CC[N+]4(C)CCC(=O)OCCCCCOC(=O)CC[N+]6(C)CCc7cc(OC)c(OC)cc7C6Cc8ccc(OC)c(OC)c8)cc3OC

InChI

1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;2*7-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;2*1-5H,(H,7,8,9)/q+2;;/p-2

Clé InChI

XXZSQOVSEBAPGS-UHFFFAOYSA-L

Informations sur le gène

human ... CHRNA1(1134) , CHRNB1(1140) , CHRND(1144) , CHRNE(1145) , CHRNG(1146)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application


  • The feasibility of the posterior tibial nerve-flexor hallucis brevis pathway applied in neuromuscular monitoring: This multicentric, controlled, and prospective clinical trial investigates a new method for neuromuscular monitoring using Atracurium besylate, providing insights into improving surgical anesthesia practices (Chen et al., 2024).

  • Onset and duration of action of escalating doses of atracurium in anesthetized healthy goats: This study assesses the pharmacokinetics and pharmacodynamics of Atracurium besylate in veterinary medicine, highlighting its efficacy and safety in non-human subjects, which is crucial for translating findings to human clinical settings (Ishihara et al., 2024).

  • Under-dosing and over-dosing of neuromuscular blocking drugs and reversal agents: beware of the risks: This editorial discusses the critical balance required in dosing Atracurium besylate to optimize patient outcomes and minimize side effects in surgical settings, emphasizing the importance of precise dosing for effective neuromuscular blockade (Hunter and Blobner, 2024).

  • Comparison of the Onset of Action, Maintenance, and Recovery of Three Weight-based Dosing of Cisatracurium in Patients with Morbid Obesity in Laparoscopic Bariatric Surgery: Although focused on Cisatracurium, this study provides comparative insights that could be applicable to similar studies on Atracurium besylate, particularly in terms of dose adjustment for specific patient populations undergoing surgical procedures (Rokhtabnak et al., 2023).

  • Neuromuscular Blockade: This piece provides a broad overview of neuromuscular blocking agents like Atracurium besylate, discussing their mechanisms and applications in clinical anesthesia, which is essential for understanding the full scope of these drugs′ utility in medical practice (Cook and Simons, 2024).

Actions biochimiques/physiologiques

Nicotinic acetylcholine receptor antagonist.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Liivi Maddison et al.
Clinical hemorheology and microcirculation, 57(4), 367-374 (2013-10-02)
Microvascular alterations and intra-abdominal hypertension are both involved in development of organ failure. It is not known whether increased intra-abdominal pressure (IAP) is associated with microcirculatory perfusion derangements. Transient increase in IAP induced by pneumoperitoneum affects sublingual microcirculation. 16 laparoscopic
P W M Janssen et al.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, 26(11), 1651-1662 (2014-09-25)
Spatiotemporal (ST) mapping has mainly been applied to ex vivo preparations of the gut. We report the results of ST mapping of the spontaneous and remifentanil-induced motility of circular and longitudinal muscles of the distal ileum in the postprandial anaesthetized
Morgan Le Guen et al.
Anesthesia and analgesia, 118(5), 946-955 (2014-04-12)
The α2-adrenergic agonist dexmedetomidine is a sedative and can be used as an adjunct to anesthetics. Our primary goal was thus to determine the extent to which dexmedetomidine reduces the requirement for propofol and remifentanil. This double-blinded, randomized study (NCT00921284)
Ignacio Garutti et al.
Anesthesia and analgesia, 119(4), 815-828 (2014-07-19)
Lung resection surgery is associated with an inflammatory reaction. The use of 1-lung ventilation (OLV) seems to increase the likelihood of this reaction. Different prophylactic and therapeutic measures have been investigated to prevent lung injury secondary to OLV. Lidocaine, a
Mario Schietroma et al.
Journal of the American College of Surgeons, 220(5), 921-933 (2015-04-05)
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor-in-Chief. An independent statistical analysis based on the summary data tables and statistical results reported in the

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique